surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers Tirzepatide cuts diabetes risk by

Hence, it is essential to take your healthcare provider onboard before including any new supplement into your diet or making any kind of lifestyle alterations, especially when you are dealing with certain health conditions or are pregnant

This means it works similarlyby mimicking the GLP-1 hormone, which helps reduce appetite, slow digestion, and stabilize blood sugar levels

Thirdly, the action of GIP on -cells has a tachyphylaxis effect

Altogether, these important findings may pave the way to developing novel antiviral strategies for treating infectious liver disease

Sherlock M, Scarsbrook A, Abbas A, Fraser S, Limumpornpetch P, Dineen R, et al